Clear All
12159 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
72603-0402-01 72603-0402 Pegflilgrastim-fpgk STIMUFEND 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte colony stimulating factor Subcutaneous Dec 29, 2025 In Use
72237-0105-01 72237-0105 Selinexor XPOVIO 80.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral Jan 5, 2026 In Use
68083-0651-01 68083-0651 Bortezomib Bortezomib 2.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Jan 6, 2026 In Use
00597-9257-59 00597-9257 Zongertinib HERNEXEOS 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral Jan 6, 2026 In Use
68083-0650-01 68083-0650 Bortezomib Bortezomib 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Jan 6, 2026 In Use
00143-9166-01 00143-9166 Denosumab-qbde XTRENBO 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jan 8, 2026 In Use
00078-1217-61 00078-1217 Lutetium Lu 177 vipivotide tetraxetan PLUVICTO 27.0 mCi/mL Radiopharmaceutical Radiopharmaceutical PSMA Intravenous Jan 15, 2026 In Use
87262-0160-02 87262-0160 Afamitresgene autoleucel TECELRA 10000000000.0 1/1 Immunotherapy T Cell Receptor (TCR) MAGE-A4 Intravenous Jan 19, 2026 In Use
43598-0125-11 43598-0125 Eribulin Mesylate Eribulin Mesylate 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous Jan 22, 2026 In Use

Found 12159 results — Export these results